DOJ subpoenas BioMarin over sponsored testing program for rare disease drugs
27 Feb 2024
The Department of Justice has issued a subpoena to BioMarin over issues with its sponsored testing programs for two of its rare disease drugs, the company disclosed in an annual SEC filing on Monday.
The subpoena seeks documents on BioMarin’s sponsored testing programs for Vimizim (elosulfase alfa), an enzyme replacement therapy for the rare genetic disease Morquio A syndrome that affects the spine and some organs. It also requests documents for its program for Naglazyme (galsulfase), another enzyme replacement therapy for people with mucopolysaccharidosis VI, a rare condition that can cause tissues and organs to atrophy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.